Spatiotemporal Assessments of Dermal Hyperemia Enable Accurate Prediction of Experimental Cutaneous Carcinogenesis as well as Chemopreventive Activity

Raymond L. Konger1,2, Zhengbin Xu3, Ravi P. Sahu1,2, Badri M. Rashid1, Shama R. Mehta1, Deena R. Mohamed1, Sonia C. DaSilva-Arnold1,2, Joshua R. Bradish1, Simon J. Warren1,2, and Young L. Kim3

Abstract

Field cancerization refers to areas of grossly normal epithelium that exhibit increased risk for tumor occurrence. Unfortunately, elucidation of the locoregional changes that contribute to increased tumor risk is difficult due to the inability to visualize the field. In this study, we use a noninvasive optical-based imaging approach to detail spatiotemporal changes in subclinical hyperemia that occur during experimental cutaneous carcinogenesis. After acute inflammation from 10 weeks of UVB irradiation subsides, small areas of focal hyperemia form and were seen to persist and expand long after cessation of UVB irradiation. We show that these persistent early hyperemic foci reliably predict sites of angiogenesis and overlying tumor formation. More than 96% of the tumors (57 of 59) that developed following UVB or 7,12-dimethylbenz(a)anthracene/phorbol 12-myristate 13-acetate (DMBA/PMA) treatment developed in sites of preexisting hyperemic foci. Hyperemic foci were multifocal and heterogeneously distributed and represented a minor fraction of the carcinogen-treated skin surface (10.3% of the imaging area in vehicle-treated animals). Finally, we also assessed the ability of the anti-inflammatory agent, celecoxib, to suppress hyperemia formation during photocarcinogenesis. The chemopreventive activity of celecoxib was shown to correlate with its ability to reduce the area of skin that exhibit these hyperemic foci, reducing the area of imaged skin containing hyperemic foci by 49.1%. Thus, we propose that a hyperemic switch can be exploited to visualize the cancerization field very early in the course of cutaneous carcinogenesis and provides insight into the chemopreventive activity of the anti-inflammatory agent celecoxib.

Cancer Res; 73(1); 1–10. ©2012 AACR.

Introduction

Field cancerization describes the increased risk for additional tumor formation following the appearance of a first tumor within an area exposed to carcinogens (e.g., UVB; refs. 1–3). However, the exact nature of the field involvement is unclear as the “field” generally cannot be visualized but is established post hoc after tumor(s) begin to appear. Recently, fiber-optic endoscope-based measurements of superficial hemoglobin (Hb) content at multiple random sites have shown that a measurable early increase in blood supply (EIBS) is detected not only in the tumor stromal environment, but is also seen in the histologically normal mucosa of the gastrointestinal tract in areas both near and remote from the neoplastic lesion (4, 5).

Moreover, EIBS may occur very early during tumorigenesis, as EIBS is seen before tumor formation in the normal colonic mucosa of azoxymethane-treated rats compared with the colons of vehicle-treated rats (6). The authors also showed that the increased hyperemia represents increased angiogenesis (6). Thus, this group proposes that EIBS is a feature of field cancerization (6). Unfortunately, these studies use random point measurements taken with a probe-based optical sensor and are limited in that they fail to visualize EIBS across a carcinogenic field. Thus, it is unclear whether EIBS exhibits a direct correlation with sites in which tumors will eventually form or represent a homogenous change to the entire field at risk.

Studies using painstaking microscopic examination of tissues have also indicated that angiogenesis can occur relatively early in tumor development (7). In this case, angiogenesis was associated with early hyperplastic changes that were multifocally or nonhomogenously distributed (7). Regrettably, the process of obtaining tissue samples for microscopic examination results in the inability to monitor these sites of angiogenesis and hyperplasia over time to verify their association with future malignancy. Thus, while these data suggest that hyperemia within the (pre)carcinogenic field is heterogeneously or multifocally distributed, the question remains as to whether these sites are spatially fixed over time. Given the inability to
determine a priori the specific site in which a tumor is likely to occur, microenvironmental changes necessary for tumor development could be missed or their significance underestimated if they are nonhomogenous in distribution, represent a minor fraction of the available surface, or are not visible on clinical inspection. In contrast, changes seen over the whole field may be readily apparent, but their importance to tumorigenesis may be overestimated. Thus, while we have experienced tremendous growth in our understanding of the microenvironment that surrounds visible tumors, we have a more limited understanding of the premalignant microenvironment due to the inability to target studies to specific sites of future tumor appearance within a cancerization field (8).

The idea that angiogenesis is turned on early during carcinogenesis is supported by studies in human tumors and in mouse models of multistage chemical carcinogenesis (7, 9–11). While the mechanisms for this early induction of angiogenesis during tumorigenesis are incompletely understood, existing tumors are known to induce angiogenesis by increased production of proangiogenic inflammatory cytokines/chemokines (inflammatory angiogenesis; refs. 10, 12). Moreover, the majority of human cancers are thought to be derived from environmental exposures and lifestyle choices (13–15). Importantly, a common feature of these environmental and lifestyle choices is that they promote inflammatory angiogenesis (10, 14, 16, 17). The importance of inflammatory angiogenesis in early stages of tumorigenesis may also be inferred by the ability of a number of chemopreventive agents, such as the anti-inflammatory COX-2 inhibitors, to suppress both the inflammatory and angiogenesis that are observed following the application of carcinogenic insults (10, 14, 16, 17).

In this study, we use a novel technique that couples optical measurement of Hb content to a noninvasive imaging platform in live animals to determine detailed spatiotemporal patterns of hyperemia formation in a large area (15 mm × 45 mm) during the course of cutaneous chemical and photocarcinogenesis. We then correlate the areas of hyperemia with subsequent tumor formation to verify that this methodology visualizes the (pre)carcinogenic field. Given the known ability of celecoxib to act as an anti-inflammatory and antiangiogenic chemopreventive agent, we also examine the effects of celecoxib on the spatiotemporal extent of hyperemia formation. We propose that this new approach to visualize EIBS provides a novel method to noninvasively visualize field cancerization early in the course of cutaneous carcinogenesis.

Materials and Methods

Chemical carcinogenesis study

Eight female FVB/n mice were treated with 7,12-dimethylbenz[a]anthracene/phorbol 12-myristate 13-acetate (DMBA/PMA) as previously described (18). After shaving and depilatory cream application to remove hair from the imaging area, the mice were imaged and Hb content assessed as described (18).

Photocarcinogenesis studies

SKH-1 hairless albino mice (Charles River Laboratories) were irradiated with 1 minimal erythema dose of UVB (2,240 J/m²) 3 times per week (Monday, Wednesday, and Friday) as previously described (19). Studies by us and others have shown that this treatment consistently results in initial tumor formation within 11 to 12 weeks of treatment (19, 20). We therefore discontinued UVB treatments after 10 weeks of treatment. This resulted in a cumulative UVB dose of 67.2 kJ/m², which exceeds a known carcinogenic cumulative UVB dose of 26.2 kJ/m² (21). For celecoxib studies (20), a chemopreventive dose of 0.5 mg of celecoxib (LC Laboratories) in 0.2 mL acetone (or vehicle alone) was applied topically immediately after each UVB irradiation and 3 times per week after discontinuation of the UVB irradiations. We imaged the irradiated mouse skin every 2 weeks, using our microvascular imaging platform (22, 23; Supplementary Methods and Supplementary Figs. S1–S3 for detailed performance characteristics). To obtain sequential images from identical areas over time, we had reference tattoos placed on each mouse to form a rectangular imaging grid. The mice were lightly sedated using ketamine/xylazine for immobilization during imaging.

Histopathologic assessment for neoplastic lesions

Visible tumors were scored on a weekly basis when exophytic growths exceeding 1 mm in diameter were observed. At the end of the study (20 weeks after discontinuing UVB treatments), all visible tumors were removed and formalin-fixed for tumor classification by a dermatopathologist. In addition, skin from areas of high and low Hb content that did not contain visibly apparent tumors were removed and were formalin-fixed. Paraffin-embedded sections were stained with hematoxylin and eosin (H&E) and examined by dermatopathologists for the presence of small tumors not visible macroscopically. Tumors were classified as previously described ref. 19 and Supplementary Methods).

Microvascular density

Following heat-induced antigen retrieval in citrate buffer, pH 6.0, formalin-fixed paraffin-embedded tissue slides were subjected to immunolabeling using rat monoclonal anti-mouse CD31 antibodies (Clone SZ31, Dianova). Stained sections were blinded and 5 random 400× fields per tissue section were counted by 3 different individuals. Microvessels were only counted where a visible lumen was observed. The mean value derived from the microvascular density (MVD) counts from all 3 individuals was used for data presentation and statistical analysis.

Statistical analysis

Nonparametric and parametric statistical analysis was used where appropriate (Supplementary Methods). Statistical significance was assigned at a P value less than 0.05.

Results

Imaging of microvascular Hb content during chemical carcinogenesis and photocarcinogenesis shows that EIBS precedes visible tumor occurrence

We first used a DMBA/PMA chemical carcinogenesis protocol to examine the spatiotemporal changes in Hb

Published OnlineFirst October 29, 2012; DOI: 10.1158/0008-5472.CAN-12-2670
content during cutaneous carcinogenesis (18). As expected, DMBA/PMA–treated mice developed tumors within 10 weeks of initiating treatment, eventually reaching approximately 2 tumors per mouse (Fig. 1A). Nine durable tumors occurred within the 12 mm × 12 mm imaging area. Overall averaged Hb content within the imaging area was unchanged in the DMBA/PMA–treated mice relative to vehicle control mice before 10 weeks but was increased in the DMBA/PMA–treated mice beginning at week 10 (Fig. 1B). Although the increased Hb content correlates with increasing tumor burden (Fig. 1C, right), we noted that all 9 tumors were seen to develop in focal areas of hyperemia that were apparent before the visible appearance of tumors. This indicates that hyperemia may represent an early step in tumorigenesis. We next mapped out progressively smaller areas of increased Hb content by using sequentially higher Hb cutoffs for threshold mapping (Fig. 1C). We found that all tumors occurred in preexisting areas of Hb content more than 1.6 mg/mL (20.4% of the imaged area). These observations suggest that our imaging methodology was measuring EIBS during early tumorigenesis. Unfortunately, the DMBA/PMA model had several deficiencies. First, the need for shaving and the use of depilatory creams made imaging difficult and could introduce hyperemia artifacts through mechanical or chemical irritation. Second, regional hair follicle cycling could contribute to some of the hyperemic response as angiogenesis is activated during the anagen phase of hair follicle development (24). Third, PMA is known to be an inducer of acute inflammation. Thus, we felt that this model had too many confounding variables for adequate analysis of EIBS.

UVB exposure represents the primary etiologic agent for nonmelanoma skin cancer (NMSC) formation (25). We therefore switched to a mouse model of photocarcinogenesis using hairless, albino SKH-1 mice (26). SKH-1 mice exhibit a defect in hair cycling in which the hair follicles permanently arrest in catagen phase (26). Thus, the permanent hair loss makes this mouse more suitable for both imaging and UVB-irradiation studies, whereas the lack of hair cycling through anagen provides a better model for studies on dermal angiogenesis. Figure 2A illustrates a typical regional pattern of dermal Hb content in non-UVB–treated SKH-1 mice. The regional variability was marked by gradual changes in Hb content, with higher levels seen overlying the spinal hump, and generally showing a symmetrical pattern on either side of the spinal midline.

Figure 1. During chemical carcinogenesis, tumors develop in regions of focal hyperemia. FVB/n mice were treated with a single dose of DMBA and repeated dosing with PMA and then followed for tumor occurrence and sequential imaging. A, visible tumor multiplicity in mice treated with DMBA/PMA. B, averaged Hb content within the imaging area (acetone)-treated mice shows a significant increase in Hb content over time for DMBA/PMA–treated mice, but not for vehicle-treated mice. For the DMBA/PMA group, the slope estimate of the linear regression for Hb content over time was significantly greater than 0 (P = 0.027). The slope of the regression line for the vehicle group was not significantly different from 0 (P = 0.383). Moreover, there was a significant difference in the slope estimates between DMBA/PMA–treated and vehicle-treated mice (P = 0.007). C, hyperemia precedes grossly visible tumor formation. Top (10 weeks after the first carcinogen treatment): left, white-light image (no visible lesion); middle, Hb content; and right, threshold mapping to define areas of high Hb content. Bottom (5 weeks later): tumors now visible along with expansion of the hyperemic area. Of 9 tumors observed in the imaging area, all occurred in areas of persistent hyperemia.
For our UVB studies, we also wished to avoid the influence of UVB-induced acute inflammation (sunburn); thus, a cumulative carcinogenic dose of UVB was administered by repetitive UVB irradiations over the first 10 weeks and then discontinued (21). Examining the Hb content beginning 2 weeks after cessation of UVB dosing allowed us to examine changes in blood supply at the time when tumors initially began to appear in this mouse model (19, 20), but after the acute sunburn effect had resolved. This also mimics human behavior, in which sun-avoidance strategies are often used after significant cutaneous photodamage is apparent or began to appear within the early weeks after UVB cessation.

While the earlier studies showed that all visible tumors developed in smaller areas of the epidermis characterized by focal hyperemia, not all areas of hyperemia were seen to develop visibly apparent tumors. We therefore euthanized the mice 20 weeks after stopping UVB treatments and biopsied skin from areas of low and high Hb content that did not contain grossly visible tumor. After histopathologic examination of H&E-stained sections, a number of papillomas and microinvasive squamous cell carcinomas were observed that were too small to be seen by visual inspection of the skin (Fig. 2D and Supplementary Table S1). Of 34 microscopically observed tumors seen in irradiated vehicle- or celecoxib-treated skin, 32 tumors occurred in areas of high Hb content. Thus, a total of 57 tumors (25 large visible tumors and 32 microscopic tumors) were seen in the much smaller areas of skin exhibiting hyperemia, whereas only 2 microscopically observed papillomas were seen in the much larger area of skin without hyperemia. Interestingly, celecoxib did not cause a significant change in the average numbers of microscopically observed tumors within the existing areas of hyperemia (Fig. 2D).

Figure 2. Focal areas of intense hyperemia precede tumor occurrence and serve to indicate sites at high risk for tumor development. A, color photographic image of an SKH-1 hairless mouse and the tattoo marks (blue) that were used to orient subsequent imaging studies. These tattoo marks are also visible in the Hb content image. B, celecoxib treatment suppresses tumor formation following UVB treatments. Tumor multiplicity in UVB-treated mice that were also treated with vehicle (Veh) or celecoxib (Coxib) were calculated as the average number of tumors per mouse. C, Hb content images and the corresponding photographs are shown for a representative mouse at 12, 16, and 20 weeks after initiating UVB treatments. Focal areas of increased hyperemia are noted to appear before visible tumor appearance (hashed circles). D, after the final imaging study (30 weeks after initiating UVB treatments), the irradiated mice were euthanized and skin free of visible tumors was excised from areas of low and high Hb content. Histopathologic assessment for the presence of small tumors visible microscopically was then done. Total microscopic tumors were normalized to the mean tissue section length for each mouse. The data show the mean tumor density per linear mm in areas of low and high Hb content for both Veh- and Coxib-treated animals. Tumors/section length (mm) were significantly higher in areas of high Hb content relative to low Hb content for both Veh-treated (\( P = 0.0436 \) for a Mann–Whitney U test) and for Coxib-treated animals (\( P = 0.0097 \) for a Mann–Whitney U test).
Celecoxib's chemopreventive activity correlates with its ability to suppress the area of treated skin that exhibits focal hyperemia rather than a global suppression of Hb content

In Fig. 3A, we contrast the typical regional pattern of Hb content in nonirradiated mouse skin with the Hb content map of a mouse 6 weeks after stopping UVB treatments. Compared with the symmetrical and gradual changes in Hb content noted in nonirradiated mice, mice treated with a carcinogenic dose of UVB showed a nonsymmetrical distribution, with focal areas of high Hb content exhibiting distinct borders and an abrupt transition to intense hyperemia. Importantly, areas surrounding these focal hyperemic areas often exhibited lower Hb content than nonirradiated mice (more blue coloration). On the basis of this focal pattern of intense hyperemia, we felt that overall averaged Hb content from the entire imaging failed to adequately assess either the Hb distribution pattern or tumor risk. It was therefore not particularly surprising that there was actually a modest and significant decrease in overall Hb content in UVB-treated skin relative to nonirradiated mice (Supplementary Fig. S5). Moreover, in celecoxib-treated mice, overall Hb content failed to show any correlation with celecoxib's chemopreventive activity (Supplementary Fig. S5).

Insofar, as averaged Hb over the entire imaging area did not seem to adequately assess the changes in hyperemia that we were observing in irradiated mice after cessation of UVB treatments, we therefore used a different analytic approach that took into account the highly focal and heterogeneous pattern of Hb content distribution. We first prepared a threshold map of hyperemic areas that had Hb content greater than 1.6 mg/mL similar to that seen in Fig. 1C. When Hb content was measured only in these smaller foci of intense hyperemia (Fig. 3B), we now saw that UVB treatment did indeed increase the amount of Hb present within the hyperemic foci. Thus, the data supported our conclusion that hyperemic areas that persist following cessation of UVB treatments represented focal areas of more intense hyperemia than that observed with normal regional blood flow. Interestingly, as with the tumor data in Fig. 2D, the Hb content within these hyperemic foci failed to correlate with the chemopreventive activity of celecoxib (Fig. 3B).

Figure 3. UVB-induced hyperemic foci contain higher Hb content than areas of high regional blood flow in nonirradiated animals, whereas celecoxib's chemopreventive activity is associated with a reduction in the area of hyperemic foci. A, representative Hb content maps are shown for the dorsal surface of a nonirradiated SKH-1 mouse and a mouse 6 weeks after cessation of UVB treatments. B, beginning 2 weeks after stopping UVB treatments, threshold maps were obtained at 2 week intervals for areas with Hb content more than 1.6 mg/mL. The average Hb content within the 1.6 mg/mL threshold mapped sites was determined for each mouse at each time point. The time (12–28 weeks) averaged mean and SD is shown for each treatment condition. The differences between UVB-irradiated and sham-irradiated groups were statistically significant (**, *P* = 0.0032 for Veh and UVB + Veh and ***, *P* = 0.0073 for Coxib and UVB + Coxib). C, after threshold mapping, the percentage of the imaging area containing Hb greater than 1.6 mg/mL is shown as a time (12–28 weeks) averaged mean and a SD for all animals (5 or 8 animals per treatment group). Celecoxib treatment results in a statistically significant reduction in the total area of involved skin with Hb content more than 1.6 mg/mL (*P* = 0.0002 for a Mann-Whitney U test). Note that all visible tumors seen in the imaging area occurred in areas of preexisting hyperemia. Visible tumor occurrence after normalizing to the percentage of the imaging area with Hb content more than 1.6 mg/mL is shown below the plot (***, *P* = 0.0002 for a Mann-Whitney U test).
In the earlier studies, we show that tumors almost invariably occur in small focal areas of intense hyperemia. However, neither the intensity of Hb content within these areas nor the tumor burden is altered by a chemopreventive dose of celecoxib. We therefore hypothesized that if celecoxib treatment does not reduce tumor risk within these foci, perhaps it reduces tumorigenesis by suppressing the total area of involved skin at risk for tumor formation. In Fig. 3C, we show that celecoxib treatment results in a suppression of the total imaging area exhibiting hyperemic foci formation by 49.1% (areas with Hb content $>1.6\text{ mg/mL}$ were 10.3% and 5.5% of the imaging area for vehicle- and celecoxib-treated animals, respectively). This reduction in the area at risk for tumor formation correlates well with celecoxib's chemopreventive activity (Fig. 2B; refs. 20, 21) As expected on the basis of the data in Fig. 2D, we show an essentially identical rate of visible tumor formation within the hyperemic areas that persist in both vehicle- and celecoxib-treated mice (0.22 and 0.21 tumors/mm²).

**Areas of focal hyperemia not only persist in the absence of a visible tumor, but also expand following cessation of UVB treatment**

As noted earlier, after discontinuing UVB treatments, areas of increased hyperemia were detected that persisted or formed over the ensuing weeks and months. Interestingly, an examination of Hb content images revealed that these persistent areas of focal hyperemia seemed to expand over time (Fig. 4A).

To assess this quantitatively, we generated threshold maps of Hb content more than 1.6 mg/mL, measured the total area of skin exhibiting Hb content above this threshold, and plotted the data at 2-week intervals after stopping UVB irradiations (Fig. 4B). As expected, UVB-irradiated mice treated with both vehicle and celecoxib showed an increase in the area of hyperemic foci over time. In addition, the expansion of hyperemic areas was seen to precede grossly observable tumor formation (Fig. 4C). As in Fig. 3C, celecoxib treatment suppressed the overall area of skin with high Hb content at each imaging time point (Fig. 4B and C).

**Hyperemic foci correspond to areas of angiogenesis**

In studies by others in rat colon, azoxymethane-induced EIBS corresponded with increased angiogenesis (6). We therefore examined whether hyperemic foci exhibited evidence of angiogenesis. In Fig. 5A–D, we show the histologic differences in skin sections obtained from nontumor-bearing areas of high and low Hb content 20 weeks after stopping UVB treatments. Following H&E staining, we observed that areas of high Hb content in UVB-irradiated skin exhibited marked epidermal

![Figure 4. UVB-induced hyperemic foci expand following cessation of carcinogenic UVB treatments.](image-url)

- **A**: Representative microvascular Hb content maps from a single UVB-treated mouse at biweekly intervals after cessation of UVB treatments reveal the spatial and temporal extent of focal hyperemia. Note that hyperemic foci not only persist, but also expand in size leading up to tumor formation. The hashed circles indicate a hyperemic foci that preceded the appearance of a tumor that became visible in week 26 and 28 (arrows). B, after threshold mapping for areas with Hb content more than 1.6 mg/mL, measured the total area of hyperemia foci over time. In addition, the expansion of hyperemic areas was seen to precede grossly observable tumor formation. The slope estimates of the linear regression for both groups were statistically significant ($P = 0.004$ for UVB+Veh and $P = 0$ for UVB+Coxib). The difference in the slopes between the 2 groups was statistically significant ($P = 0.021$).
hyperplasia, a hypercellular dermis consistent with increased inflammatory cell infiltrates and increased numbers of small vessels (Fig. 5D and E). In contrast, irradiated skin obtained from areas of low Hb content were largely normal, with some focal areas of mild epidermal hyperplasia and mild increase in dermal hypercellularity (Fig. 5B). In contrast, in nonirradiated control mice there was no apparent histologic change in areas of high and low regional blood flow (Fig. 5A and C). To verify that focal hyperemia was associated with increased angiogenesis in irradiated mice, we assessed MVD. In Fig. 5F, we show that MVD was significantly greater in areas of high Hb content in UVB-treated mice compared with areas of low Hb content. Celecoxib treatment also had no significant effect on MVD in the smaller hyperemic areas that persisted despite celecoxib treatment. However, this was expected as we had already shown that celecoxib had no significant effect on Hb content within hyperemic foci (Fig. 3B).

UVB-induced acute erythema reactions (sunburn) are uninformative about future tumorigenesis or the chemopreventive efficacy of celecoxib

Our photocarcinogenesis studies were designed to remove potential interference from UVB-induced acute hyperemia. As we expected, a marked increase in Hb content was observed using our imaging approach in UVB-irradiated mice 72 hours after the final irradiation (Fig. 6A, top left). This increase in Hb content was also visually apparent as an area of erythema (sunburn) in the photographic image (Fig. 6A, bottom left). Importantly, within a few weeks after discontinuing UVB treatments, visible erythema disappeared and was accompanied by a return to a largely normal pattern of regional Hb content (Fig. 6A, top right). It is also important to note that transient UVB-induced hyperemia failed to correlate with sites of eventual tumor formation (Fig. 6A, hashed circle). Nor did visible erythema reactions correlate with the chemopreventive
activity of celecoxib. This subjective assessment was verified by measuring the acute UVB-induced erythema reaction using a narrow-band reflectance spectrophotometer (Mexameter; Fig. 6B; see Supplementary Methods).

Discussion

Field cancerization is clearly present in human nonmelanoma skin cancer, in which field treatments are often necessary to treat multiple premalignant actinic lesions that occur on sun-damaged skin (27). Multiple theories have been proposed to explain how a cancerization field develops (3, 28). However, it is difficult to firmly establish the nature of early field development when the field cannot be visualized before grossly visible tumor formation. In our study, we provide multiple lines of evidence that hyperemia is an early marker of field cancerization and that our imaging approach visualizes the cancerization field in experimental cutaneous murine carcinogenesis: (i) tumors almost invariably formed in areas of focal hyperemia that persist long after the cessation of carcinogenic UVB exposures. (ii) Hyperemic areas in which tumors formed represented a minor fraction of the total treated area and were multifocal in nature. (iii) The ability of celecoxib to suppress tumor formation correlated well with its activity of celecoxib. A, representative microvascular Hb content images (top) and photographic images (bottom) are shown showing the intense hyperemia (top) and erythema (bottom) that is still evident 72 hours after the final UVB dose. A Hb content image and photographic image of the same site 17 days later show resolution of the acute hyperemia and erythema response. Acute hyperemia did not correlate with the future appearance of tumors. The dashed circles indicate a site of a tumor that appeared 10 weeks after stopping UVB treatments. B, erythema was measured using a narrow-band reflectance spectrophotometer (Mexameter) in the fifth week of UVB treatments (72 hours after the previous UVB dose; \( P = 0.0515 \) for a Kruskal–Wallis test). Results represent the mean ± SD of the erythema measurements \( n = 2 \) nonirradiated and 5–6 irradiated mice per group).

Neither clinically apparent erythema (sunburn) nor averaged subclinical Hb content predict the site of future tumor formation or the chemopreventive activity of celecoxib. A, representative microvascular Hb content images (top) and photographic images (bottom) are shown showing the intense hyperemia (top) and erythema (bottom) that is still evident 72 hours after the final UVB dose. A Hb content image and photographic image of the same site 17 days later show resolution of the acute hyperemia and erythema response. Acute hyperemia did not correlate with the future appearance of tumors. The dashed circles indicate a site of a tumor that appeared 10 weeks after stopping UVB treatments. B, erythema was measured using a narrow-band reflectance spectrophotometer (Mexameter) in the fifth week of UVB treatments (72 hours after the previous UVB dose; \( P = 0.0515 \) for a Kruskal–Wallis test). Results represent the mean ± SD of the erythema measurements \( n = 2 \) nonirradiated and 5–6 irradiated mice per group).

Our observation that both hyperemic foci and tumor risk are not homogeneously distributed but rather are limited to a small heterogeneous segment of the entire carcinogen-treated surface is important. Our methodology could potentially allow investigators to actually visualize this multifocal "field" to allow targeted biopsies to assess locoregional changes associated with early events in carcinogenesis, and could provide a method to assess the efficacy of chemopreventive agents. Moreover, the ability to target sites at high risk for tumor formation for longitudinal studies in live animals will provide important information about the early premalignant changes that are specific to the cancerization field. Our methodology would be of particular importance if validated in human studies, such as individuals with significant cutaneous photodamage or early premalignant actinic disease that are at high risk for nonmelanoma skin cancer formation. Currently, studies in live volunteers are constrained by the limited amounts of tissue that can be ethically obtained. High variability due to sampling bias results in the need for high numbers of volunteers to obtain statistically valid data or restricts studies to sites of visible premalignant or malignant lesions.

Studies of carcinogen-induced malignancy in skin and other tissues indicates that the angiogenic switch can be triggered much earlier during the carcinogenic sequence, occurring as early as the sustained hyperplastic response (7, 29). This differs somewhat from the classic model of tumor-induced angiogenesis, in which an existing avascular tumor switches on proangiogenic signals that provide the increased blood supply needed for tumor expansion and progression (7, 29). However, this classic model of an "angiogenic switch" is generally
observed with the use of various oncogene-driven mouse models (29). Thus, our findings support the idea that the angiogenic switch occurs very early during cutaneous carcinogenesis rather than the classic model, whereby the angiogenic switch occurs later in existing avascular visible tumors. However, further studies are necessary in our model to verify that angiogenesis is responsible for the hyperemic foci present before the time when tumors are evident.

One of the interesting findings of our study is that celecoxib’s chemopreventive activity correlates directly with its ability to decrease the total surface area exhibiting hyperemic foci. In contrast, celecoxib failed to suppress either tumor formation or the intensity of the hyperemia within these foci. A number of possible explanations could explain these observations, all of which would require further studies to verify. One hypothesis would be that the hyperemic foci represent patches of proliferating (pre)malignant keratinocytes that produce the proangiogenic cytokines necessary to trigger increased dermal blood supply. COX-2 inhibitors exhibit potent effects on the growth and survival of normal and neoplastic epidermal keratinocytes (30, 31). Thus, celecoxib treatment could limit the clonal expansion of these (pre)malignant epidermal patches, thus limiting their size. Alternatively, COX-2 inhibitors are known to suppress UVB-induced inflammation and this is closely associated with their antineoplastic activity (21, 26). Moreover, a persistent inflammatory stromal environment is associated with both angiogenesis and increased overlying epithelial tumor development (9, 10, 32). Thus, it is possible that celecoxib suppresses the formation of persistent inflammatory foci, which in turn suppress angiogenesis and overlying tumor development. In this case, it is unclear why some hyperemic foci are resistant to the effects of celecoxib. A trivial explanation would be that these areas failed to receive adequate levels of celecoxib due to variable topical delivery. However, this seems highly unlikely given that each mouse was treated on multiple occasions over the 30-week course of the study. Still, repeating these studies using systemic delivery of celecoxib would be of interest.

The risk of tumor development is well known to persist for years after the removal of carcinogenic insults. A number of theories have been advanced to explain these observations. This includes dormant tumors that are induced to progress due to an angiogenic switch that triggers increased blood supply (29) or the acquisition of proliferative self-sufficiency or survival advantage mediated by mutagenic events or a nurturing microenvironment (8, 33). Unfortunately, the inability to specifically identify tissue sites at the earliest stages of tumorigenesis limits the ability to define why risk for tumor development persists. Our data suggest that an unknown mechanism exists that sustains and actually expands areas of focal hyperemia after removal of a carcinogenic insult. As mentioned earlier, this could be due to continued clonal expansion of (pre)malignant patches or possibly the presence of inflammatory feedback loops driving persistent inflammatory angiogenesis. Identifying the engine that drives the persistence and expansion of these hyperemic zones could provide answers to how risk for tumor formation persists in individuals who undertake risk-avoidance behavioral changes.

Disclosure of Potential Conflicts of Interest

R. Konger, Z. Xu, and Y.L. Kim have ownership in a Provisional Patent Application. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: R.L. Konger, S.J. Warren, Y.L. Kim
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Z. Xu, R.M. Rashid, S.R. Mehta, D.R. Mohamed, S.C. DaSilva-Arnold, S.J. Warren, Y.L. Kim
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R.L. Konger, Z. Xu, D.R. Mohamed, J.R. Bradish, S.J. Warren, Y.L. Kim
Writing, review, and/or revision of the manuscript: R.L. Konger, J.R. Bradish, Y.L. Kim
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R.L. Konger, Z. Xu, R.P. Sahu, R.M. Rashid, S.R. Mehta, D.R. Mohamed, Y.L. Kim
Study supervision: R.L. Konger, B.M. Rashid, Y.L. Kim

Acknowledgments

The authors thank Dr. Jeffrey Travers for his insights and editorial commentary.

Grant Support

This study was supported by the funding from the NIH: R01HL062996, R21ES017497, R01AR053710, and R25CA128770. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 USC Section 1734 solely to indicate this fact.

Received July 5, 2012; revised October 16, 2012; accepted October 17, 2012; published OnlineFirst October 29, 2012.

References

Spatiotemporal Assessments of Dermal Hyperemia Enable Accurate Prediction of Experimental Cutaneous Carcinogenesis as well as Chemopreventive Activity

Raymond L. Konger, Zhengbin Xu, Ravi P. Sahu, et al.

Cancer Res  Published OnlineFirst October 29, 2012.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-12-2670

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2012/10/30/0008-5472.CAN-12-2670.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.